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doi:10.1016/j.ijsu.2007.03.004Abstract Vascular smooth muscle tumors are very rare. They can be benign or malign. Intra-
vascular leiomyomatosis is a benign neoplasm that extends through the veins and caries signif-
icant morbidity. Angioleiomyoma is a benign neoplasm of the extremities that caries minimal
morbidity. Vascular leiomyosarcomas are malign neoplasms derived from vascular smooth
cells. They are usually localized to the inferior vena cava, but can also arise from the pulmo-
nary arteries or veins or other peripheral vessels. This study reviews literature for epidemiol-
ogy, clinical presentation, diagnosis and management of patients with vascular smooth muscle
tumors.
ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Vascular smooth muscle tumors are very rare and include
a variety of neoplastic lesions characterized histologically
by their similarity to adult smooth muscle tissue.1 They can
be benign or malignant, with an incidence of 300 benign
tumors and 1 malignant tumor per 100,000 soft tissue
tumors.1,2 Intravenous leiomyomatosis (IVL) is a benign
smooth muscle neoplasm that extents non-invasively,
through the venous system, increasing however the risk of
morbidity and mortality.3 Angioleiomyoma is a benign tu-
mor arising from the vascular smooth muscle and it occurs
in the extremities and the head. It is also known as angio-
myoma, vascular leiomyoma, or dermal angioma.4 Vascular7 Surgical Associates Ltd. Publishleiomyosarcomas (LMS) are unusual malign tumors that at-
tack arteries less often than veins. Lesions of the inferior
vena cava represent the largest subgroup of these neo-
plasms.5 Other primary sites are involved far less fre-
quently. Pulmonary vein LMS are extremely uncommon
and are outnumbered in the literature by those of the pul-
monary artery.5 This study reviews literature for the epide-
miology, clinical presentation, diagnosis and management
of patients with IVL, angioleiomyoma, and vascular LMS.
Intravenous leiomyomatosis
Etiology
IVL is a rare smooth muscle cell tumor that grows within the
venous channels without invading them.3 About 200 cases
have been reported in the literature so far.3 It was firsted by Elsevier Ltd. All rights reserved.
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of this neoplasm is not entirely known. Two contrasting the-
ories have been presented, both of which have supporting
evidence.1 The first one suggests that the neoplasm arises
from estrogen-induced smooth muscle cell proliferation in
the venous wall of the uterine veins, while the second
one suggests that the neoplasm arises from uterine leio-
myomas that invade the venous system.7 The extension of
the tumor is mostly through the uterine veins and can prog-
ress along the veins into the inferior vena cava. Further ex-
tension into the right-sided cardiac chambers will lead to
intracardiac leiomyomatosis. More than 100 cases of intra-
cardiac leiomyomatosis have been reported in the English
literature until now (Table 1).3
Epidemiology
Leiomyoma shows a predilection for pre-menopausal
women.7,8 Half of the patients have had prior pregnancies.2
Since 1900, only 73 cases of cardiac leiomyomatosis have
been reported1 and 60% of the reports were within the
last 15 years. However, it is believed that diagnosis is still
significantly underestimated3 because it is easily missed
particularly at early stages when the tumor’s extension re-
mains inside the small vessels of myometrium and cannot
be detected with facility. The median age of diagnosed
cases is 47 years.3
Clinical presentation
Clinical onset of these tumors usually reflects the extension
of the lesions. The majority of the patients present with
numerous non-specific symptoms that include vaginalTable 1 Cases on intracardiac leiomyomatosis from 1900 until
No. Reference
1 Lam et al. Review of cases with intracardiac
extension between 1900 and 2003. Int J Gynecol
Cancer 2003;89:175e80
2 Burke et al. Pathology 2004;36:202e3
3 Saitoh et al. Gynecol Obstet Invest 2004;58:168e70
4 Lam et al.3
5 Sasaki et al. Nippon Naika Gakkai Zasshi 2004;93:142e4
6 Jerez-Anera et al. Rev Esp Anestesiol Reanim 2004;51:4
7 Sakamoto et al. Jpn Thorac Cardiovasc Surg 2004;52:148
8 Nishizawa et al. J Am Coll Surg 2004;198:842e3
9 Feng et al. Chin Med Sci J 2004;19:55
10 Uchinca et al. Obstet Gynecol 2004;103:1068e70
11 Topcuoglu et al. Ann Thorac Surg 2004;78:330e2
12 DeRubertis et al. J Vasc Surg 2004;40:554e8
13 Bennett et al. Nat Clin Pract Cardiovasc Med 2005;2:369
14 Murphy et al. EJVES Extra 2005;9:4e6
15 Moorjani et al. J Card Surg 2005;20:382e5
16 Thukkani et al. Ann Thorac Surg 2005;79:707e9
17 Ozer et al. Echocardiography 2005;22:514e6
18 Kocica et al.6
19 Castelli et al.10
RA, right atrium; RV, right ventricle.bleeding, pelvic pain, dyspnea, syncope, and congestive
heart failure.2,7 Other symptoms include fatigue, abdomi-
nal pain, ascites, peripheral edema, and deep vein thrombo-
sis.3 Predominant cardiac symptoms have been reported in
10% of the patients,1 and in 50% of them uterine enlargement
is observed. However, the patients may be completely
asymptomatic,1 and correct diagnosis relies on ahigher index
of suspicion.
IVL should be suspected when extrauterine tumor is
observed in the form of wormlike or nodular plugs within
pelvic veins3 during operation or unexpectedly after micro-
scopic examination of a hysterectomy specimen.
Imaging
Echocardiography
In patients with intracardiac leiomyomatosis, transthoracic
echocardiography can show the presence of a free-flowing
echogenic intracardiac mass, in the right cavities or in the
pulmonary arteries. Tricuspid regurgitation can also be
shown.9 Transesophageal echocardiography usually reveals
an elongated, mobile, serpent-like polypoid mass proceed-
ing from the inferior vena cava into the right atrium and
ventricle, passing through the tricuspid valve.
Computed tomography and magnetic resonance
Magnetic Resonance and 16-, 32-, 64- and 128-slide multi-
detector computed tomographic angiography are the most
sensitive methods to reveal IVL even in early stages without
intracardial leiomyomatosis. Heterogeneous uterine mass
that can be seen unilaterally or bilaterally into the iliac
veins and in the inferior vena cava is the most common
finding. Masses in the subhepatic region extending down tonow
Cases Localization Surgery
68 RA 31 None 3
RV 31 Incomplete excision 17
PA 6 One-stage 19
Two-stage 29
1 PA Death before surgery
1 RA One-stage
2 RA Two-stage
1 RA One-stage
0e3 1 RA One-stage
e51 1 RV One-stage
1 RA One-stage
1 RA Two-stage
1 RV One-stage
1 RV Two-stage
1 RA Two-stage
e72 1 RV One-stage
1 RA One-stage
1 RV One-stage
1 RV Two-stage
1 RA Two-stage
1 RV Two-stage
1 RA Two-stage
Vascular tumors 159the pelvis, tumor masses within the ovarian veins or the
renal veins have also been reported.3
Macroscopical, immunological, and histological
findings
Excised tumors are often rubbery with a tan to whitish
appearance.7 The largest lesion ever reported was 35 cm in
length.7 IVL are often free-floating and elongated. Grossly,
the lesion is characterized by coiled masses within the my-
ometrium and serpentinous extensions into the uterine
veins.1,2
In immunological studies the tumor cells are diffusely
and strongly positive on smooth muscle markers, including
desmin and smooth muscle actin,3 confirming their smooth
muscle nature. They show bizarre nuclear morphology with
hyperchromatic multilobulated nuclei. The mitotic activity
is low, with mitotic index of less than 1 per 50 high-power
fields. The cells range from highly cellular spindle cell
masses to cellular ones marked by fibrosis, hydropic
change, and perivascular hyalinization.1,2 Tumors positive
for CD34 are often non-thrombogenic due to the presence
of an endothelial surface layer.1,7
Several reports included immunohistochemically posi-
tive reactions of the intravascular parts of the tumor9 with
antibodies against estrogen and progesterone receptors,
and it was suggested that a high concentration of serum
estradiol and a high level of tissue estrogen receptor are
related to the IVL and potentially influence the growth of
the smooth muscle cells.9,10 The latter theory could be po-
tentially confirmed because the highest incidence rate of
recurrence is found in patients with normal ovarian activ-
ity. It was also suggested that occasionally hormonal ther-
apy should be considered in cases of unresectable
residual tumors.9 The detection of cytoplasmic estradiol
and progesterone receptors in both the intravascular tumor
and leiomyosarcoma would allow consideration of the use
of an antiestrogen such as Tamoxifen to control the prog-
ress of the disease, although there is not any report of
efficacy in the literature.9Treatment
Surgical resection is the treatment of choice.1,2,7,10 Attempts
must be made to remove the entire neoplasm, which usually
involves hysterectomy.1 Incomplete excision can result in
recurrence of the neoplasm. Recurrence rate of 30% from
7 months to 17 years follow-up has been reported.2,7 In
a study by Butany et al.1 there was a 12.5% of recurrence
after complete excision in 8.6 months’ follow-up. When
treating IVL, even if risk of pulmonary embolism is low, a tem-
porary inferior vena cava filter can prevent from potential
embolism during surgical maneuvers. When both abdominal
and thoracic approach is needed, a two-stage operation
can be considered. The slow growth of the tumor allows
a safe interval between two major surgical procedures. The
advantages of two-stage strategy are the shorter operative
times, despite the risks of a second general anesthesia, and
the less risk of bleeding, as systemic heparinization manda-
tory for one-stage cardiopulmonary bypass, is actually
avoided. In the thoracic approach the tumor should beresectedbelow the level of the renal veins to facilitate easier
vascular control in the second-stage laparotomy,3 because
higher vascular control requires mobilization of the liver
via a right thoracoabdominal incision, with its associated
morbidities. In addition, clamping of the cava above the he-
patic vein congruence will significantly reduce the preload,
necessitating an axillofemoral venous bypass.3
It has been suggested that recurrence may show the
same pattern even after hysterectomy and bilateral adnex-
ectomy. This shows that the tumor growth is independent
of the presence of the uterus and although histologically
benign, might be considered clinically malignant.10 When
recurrence is seen, reintervention is actually universally
recommended to achieve long-term disease-free survival.10
Angioleiomyoma
Etiology/epidemiology
Minor trauma, venous stasis and hormonal changes, espe-
cially estrogenic, have been proposed as etiological fea-
tures. The presence of chronic inflammatory infiltrates in
some lesions supports the venous stasis theory.4 Another
theory suggests that the lesions could be hamartomatous
as has been demonstrated by the presence of mature fat
cells.4
They account for 5% of all benign neoplasms of soft
tissues and their prevalence in eastern South Africa is 10
times that of the Caucasian population living in temperate
climates.4
Histology
In 1973 Morimoto11 studied 241 cases of angioleiomyoma
and classified them into three histological types:
1. Solid: The most common type which has closely com-
pacted smooth muscle and many small, split-like vascu-
lar channels. This type of tumors is three times more
common in females than in males.
2. Venous: Thick, easily identifiable muscular walls distin-
guish this type. These tumors occur more commonly in
males.
3. Cavernous: The vascular channels are dilated with less
smooth muscles. This is the most uncommon type.
These tumors occur 4 times more common in males
than in females.
Morimoto11 also grouped these tumors into two groups:
the larger group of extremity tumors, where they are
mainly of the solid type, often painful, and the smaller
group of head tumors, where they are usually of the venous
type and painless.
Clinical presentation
The typical finding is a solitary, small, slow-growing, firm,
mobile, subcutaneous nodule. Most of them are less than
2 cm in size.4 Pain is the most striking clinical feature of
angioleiomyoma. It is often paroxysmal and is provoked
by exposure to cold and wind.4
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On ultrasound, it shows well defined margins and a homo-
geneous structure, suggesting benign nature. Color-duplex
shows high resistance in intratumor arteries, suggesting the
presence of muscular arteries.4 Magnetic resonance shows
the tumors hypertensive and isointensive to skeletal mus-
cle. For an extremity mass with mixed areas of hypes and
isointensivity to skeletal muscle of T2-weighted images
and hypointense rim, a diagnosis of muscular leiomyoma
should be considered.4
Treatment
Simple excision for biopsy is often curative.4 Recurrences
have occasionally been reported.4
Leiomyosarcoma
Etiology/epidemiology
Unlike IVL, LMS are malignant neoplasms derived from
vascular smooth cells. They represent about 5e7% of all
soft tissue sarcomas.12e15 They most often affect the gastro-
enteric systemand theuterus, less frequently the respiratory
apparatus, and rarely the limbs.16 The adult population is
most susceptible, particularly the women.12e15 A theory for
the explanation of female predominance is that growth and
proliferation of the smooth muscle is likely to be influenced
by pregnancy and estrogenic stimulation. LMS can be distin-
guished as intraperitoneal and retroperitoneal, cutaneous,
subcutaneous and vascular neoplasia.16
Vascular LMS represent only 2% of all these neoplasias
and about 200 cases have been reported in the litera-
ture.16e18 Veins are involved five times more often than
arteries and particularly the vena cava, which alone
represents 50% of all localizations, followed by the big sys-
temic veins and the great saphenous.19 Arterial LMS are
equally distributed between pulmonary artery (the most
frequent localization, approximately 50% of the cases16)
and other systemic arteries. Review of the published liter-
ature identified 19 reported cases of peripheral (non pul-
monary/non aortic) arteries LMS.17,19e36 They refer to 9
women and 10 men. These 19 patients ranged from 33 to
79 years old with an average age of 58.6 years. Since the
initial report by Perl in 1871, there have been 218 cases
of LMS of the inferior vena cava reported,2,37,38 and over
the last 18 years 70.4% of reported LMS occurred in the in-
ferior vena cava.1 The male to female ratio is 3:7 with
a mean age of 56.9  7.9 years.1 LMS have been reported
to arise in the pulmonary arteries and veins with a ratio
of 20:1.5 Pulmonary vessel LMS has a male to female ratio
of 1:2.1 Four cases of LMS of the portal and large mesen-
teric veins have been reported39 in the literature until now.
Clinical presentation
Abdominal pain is the most common symptom for neo-
plasms occurring in any region of the body and is referred
from 45.7% of the patients.1 Deep vein thrombosis or ve-
nous distension are observed in 12% and 20% of the patientsrespectively. Inferior limb edema is also a common symp-
tom.40 When the localization is a pulmonary vessel, symp-
toms like palpitation, dizziness, syncopal attacks, dyspnea
and eventual right-heart failure can be present.2,38 In pe-
ripheral artery localization the main symptoms are pain
and vascular insufficiency. However, in approximately one
third of the patients the diagnosis is incidental as the pa-
tients are asymptomatic. Therefore, the diagnosis is often
delayed, despite the tumor’s large size, and it remains
asymptomatic for a long tine.
Diagnosis
Common laboratory tests reveal albuminuria when the
hepatic or renal veins are involved. Polycythemia andmicro-
angiopathic anemia can also be observed.41 Gastrointestinal
and intravenous contrast studies demonstrate an extrinsic
mass effect when the localization is the inferior vena cava.
In ultrasonography of the abdomen the tumor appears as
a mass with homogeneous or heterogeneous sound pat-
terns.42e53 Doppler ultrasound gives information about pa-
tency of the portal or systemic venous system.43,44,50
Computed tomography and magnetic resonance
Computed tomography and magnetic resonance are the
most sensitive examinations and confirm the presence of
the tumor, its pattern or growth, relationship to the
surrounding structures, and the presence of caval obstruc-
tion. On computed tomography the tumor appears as low
density, solid, or heterogeneous mass compressing or
silhouetting, involving or arising from the inferior vena
cava.41,43,54e61 Magnetic resonance gives similar informa-
tion but the sagittal section is more informative as to the
extent of the tumor and tumor thrombous.41,45,50,52,53,60e62
Angiography
On angiography, LMS exhibit variable degrees of vasculabi-
lity.43,55,57,62e64 Hypervascular tumors derive their blood
supply from the hepatic artery or its branches, adrenal, lum-
bar, gastric, pancreatoduodenal, or gastroduodenal artery.
Other findings can be distortion, stretching, or compression
to adjacent structures. Angiography cannot differentiate
caval LMS from retroperitoneal LMS. In arterial
localization of LMS, the arteriogram may confuse it with
pseudoaneurysms.36
Histology
LMS of the inferior vena cava exhibits a typical pattern of
interlacing sweeping bundles of spindle-shaped cells with
elongated, blunt-ended nuclei with a tendency to pali-
sade.41 Mitotic figures can vary within the same tumor.
Mononuclear giant cells can be present at a variable de-
gree, and areas of necrosis are commonly seen. Masson’s
trichrome and Van Gieson’s stain indicate the presence of
collagen tissue. Immunohistochemical and ultrastructural
studies reflect features found in soft tissue sarcoma of
other sites. The tumor cells display desmin, vimentin, and
smooth cell actin, but not S-100 protein.41,58,65,66 A high
desmin immunoreactivity rate exceeding that seen in other
soft tissue LMS is also noted.41 Myofibrils, intracytoplasmic
vesicles, and occasional tight junctions between tumor
cells are described.41,42,66,67
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LMS of the inferior vena cava are considered to be slowly
growing tumors. In a review of 89 resected and 43 non-
resected LMS of the inferior vena cava,41 three cases of
rather rapid growth rate were identified.62,64,68 In these
cases the tumor was not present on previous laparotomy
performed 6e24 months for unrelated disorders.
The tumor metastasize late in the course of the disease
and spreads mainly systemically and most commonly to the
lungs and the liver, but no organ is exempt. Lymph node
metastasis occurs less frequently.41
Management
Surgical
Complete surgical resection is the mainstay of treatment
for vascular LMS.69 Whenever possible, surgical resection
should be used to completely remove the primary tumor in-
tact and en bloc with any directly involved adjacent struc-
tures that can be sacrificed. Ideally, a margin of uninvolved
normal tissue would be resected with the tumor, given the
high incidence of local recurrence when lesser resections
are performed.36 The necessary disruption of the vascular
system will usually require vascular reconstruction after re-
section. The location of the primary tumor and its extent
will dictate the type and complexity of the reconstruction
required to reestablish arterial flow or caval flow. Tumor
thrombectomy alone, even if not curative, can prevent
death from liver failure and right heart outflow tract ob-
struction in some cases.41
Radiation
Adjuvant radiation therapy, either pre- or postoperatively,
decreases the rates of local recurrence of LMS.36 Some au-
thors69,70 suggested that high-dose-rate intraoperative
radiation improves local control; however, the utility of
radiation therapy in this setting should be ultimately be de-
termined by prospective randomized trials.
Chemotherapy
Effective systemic chemotherapy for the treatment of LMS
of soft tissues is at least controversial.36 Toxicity is signifi-
cant, and systemic chemotherapy would only be considered
for large high-grade tumors, recurrent tumors, and meta-
static disease. Appropriate follow-up for these tumors
should monitor for focal recurrence (with CT or MRI
every 3e4 months36) and for pulmonary metastasis (with
CT of chest every 4e6 months36) during the first 5 years
postoperatively.
Prognosis
Prognosis following complete resection varies according to
the histologic features of the primary tumor. In a review of
inferior vena cava LMS,41 in Grade I (with minimal, few, or
less than five mitotic figures per high-power field), survival
with no evidence of disease for 3 months to 13 years was
noticed in 64.3% of the patients. In grade II (moderately dif-
ferentiated tumor), survival with no evidence of the dis-
ease for 9 months to some years was observed in 60% of
the patients, and local recurrence developed 20%. In gradeIII (poorly differentiated tumor, with frequent or more than
10 mitotic figures per high-power field), survival with no ev-
idence of the disease for 2e15 months was seen in 57% of
the patients, whereas systemic spread occurred within
3 months to 2 years in 43%. However, other authors62 did
not find a correlation between mitotic activity and clinical
outcome.
Conclusions
Vascular smooth muscle neoplasms that extend through
blood vessels are extremely rare, difficult to be diagnosed
early, and complex to treat.
IVL is a benign smooth muscle cell tumor that grows
within the veins. It is a complex disease that caries
significant morbidity, and multidisciplinary surgical ap-
proach is the key for an accurate tumor excision.
Angioleiomyoma is a benign tumor which commonly
presents between the third and fifth decade of life. It is
painful in over half of the cases. It should be considered in
the differential diagnosis of painful nodular lesions of the
extremity. It causes minimal morbidity and excision is
usually curative.
Vascular LMS are potentially aggressive neoplasms. The
management of these tumors is today oriented toward
preoperative staging and complete surgical resection with
vascular reconstruction. However, prognosis depends also
on the size and the grade of the tumor. The only
therapeutic modality associated with prolonged survival is
complete surgical resection with clean margins, followed
by adjuvant radiation therapy.
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